ChemOn Inc. Overview
CorestemChemon is a small-cap Korean "hybrid" biotech that pairs a revenue-generating non-clinical CRO (the former ChemOn, founded in 2000 as Korea's first private GLP safety-testing laboratory) with a high-risk stem-cell drug developer (the former Corestem). The CRO division performs toxicology, safety pharmacology, efficacy and bioanalytical studies for drug, biologic, medical-device, food and chemical developers, historically running 1,000–1,500 studies per year, and supplies essentially all group revenue. The drug division's sole marketed product, NeuroNata-R (lenzumestrocel), is an autologous bone-marrow mesenchymal stem-cell therapy for ALS conditionally approved in Korea in 2014; its global Phase 3 missed its primary endpoint in December 2024, but Korea's MFDS approved a narrowed label for slow-progressing patients in May 2026. The company is loss-making (FY2025 operating loss KRW 21.2 bn on revenue of KRW 20.2 bn), thinly capitalised, and its equity story hinges on CRO recovery and a US BLA targeted for 2027.
Company's own description
In its investor materials CorestemChemon describes itself as a "Total Health Care Company" possessing a full-cycle drug-development system — from early non-clinical experimentation through Phase 1–3 clinical capability — with a stated vision of improving quality of life through new-drug development (IR decks, April/June 2024). The company frames the 2022 merger around three pillars: an in-house non-clinical database spanning early experiments to Phase 3 entry, financial stabilisation via the CRO's recurring revenue, and scientific synergy between the CRO's testing infrastructure and the stem-cell pipeline.
In its FY2025 business report (as summarised by IB Tomato, April 2026), the company attributes the revenue decline to reduced CRO testing orders amid a global downturn and a prolonged slump in Korea's bio-industry, and to the suspension of NeuroNata-R manufacturing after Q1 2025 pending new-site certification and a label-change application.
Independent characterisation
Functionally, CorestemChemon is a Korean non-clinical CRO carrying a binary stem-cell option:
Economic engine: The CRO division (former ChemOn) is a fixed-cost-heavy service business — GLP facilities, specialist toxicologists and pathologists, animal husbandry — whose gross margin swings sharply with utilisation. thebell (Sep 2026) notes that when utilisation is low the cost-of-sales ratio exceeds 100%, but incremental revenue drops largely to gross profit. In Q1 2026 the cost-of-sales ratio was 136%; in Q2 2026 it improved to 102.5%.
Option value: NeuroNata-R is an autologous, intrathecally administered cell therapy for ALS with ~400+ patients treated in Korea since 2014 (Money Today, Jun 2026). Its value depends on (i) domestic commercial restart from the new Osong plant and (ii) a US path via FDA Type C → RMAT → BLA.
Balance-sheet constraint: Cash of only KRW 2.1 bn at end-FY2025 against KRW 24.1 bn of borrowings due within a year (IB Tomato, Apr 2026) makes the CRO recovery an existential, not merely incremental, variable.
Revenue model
| Revenue type | Description | Share of revenue | Source |
|---|---|---|---|
| Contract research services (fee-for-study) | Non-clinical safety/efficacy studies billed per contract, recognised over time by percentage of completion | 98% of H1 2026 revenue (KRW 9.5 bn of 9.7 bn); ~98% of FY2025 | thebell Sep 2026; IB Tomato Apr 2026 |
| Product sales (cell therapy) | NeuroNata-R manufactured per patient (autologous) and sold in Korea | ~1% of FY2025 (≈KRW 0.2 bn); ~4% of FY2024 (≈KRW 1.1 bn); 13% in FY2019 (pre-merger consolidated) | IB Tomato; SK Securities 2020 |
| Licensing / technology transfer | Historically minimal (1% in FY2019); management cites prospective pre-approval out-licensing of NeuroNata-R as a contingent funding source | ~0% currently | SK Securities 2020; IB Tomato |
| Government R&D grants | National project funding (≥KRW 5.4 bn secured in 2026) — booked within CRO activity | Included in CRO orders | thebell Sep 2026 |
| Subscription | — | 0% | — |
Value-chain position, customers and end-markets
Value chain: The CRO sits between discovery/lead optimisation and first-in-human trials, generating the GLP safety package required for IND/CTA filings. Through a 2021-era MOU with clinical CRO Dream CIS (signed by then-ChemOn CEO Song Si-hwan), ChemOn positioned itself to offer an integrated non-clinical-to-clinical service (Daily Pharm).
Customer types: Korean pharma and biotech developers, medical-device makers, functional-food and cosmetics-ingredient developers, chemical registrants, government research programmes, and — increasingly — overseas institutions (a contract with a Vietnamese university hospital in 2026).
Substance mix: The September 2024 IR deck's chart of studies by test-article type shows the largest single category at 46.5% of studies (understood to be synthetic pharmaceuticals), with the balance across biologics, chemicals, food/health-functional food, cosmetics, natural-product drugs, medical devices and nanomaterials (0.2%). Exact mapping of the remaining percentages could not be reliably extracted.
End-markets: Korean drug and device R&D (dominant); emerging adjacent-industry testing (functional foods, cosmetics materials); ALS therapeutics (drug division).
Strategy
Stated strategic themes (company IR and management statements)
-
Full-cycle drug development ("Total Health Care Company"): leverage in-house non-clinical capability to accelerate the stem-cell pipeline from discovery to Phase 3.
-
CRO as self-funding engine: restore CRO quarterly revenue to KRW 10 bn+, at which level management says all personnel and operating costs are covered (thebell, Jan 2026); first-order target is a return to quarterly gross profit (thebell, Sep 2026).
-
Precision-targeted NeuroNata-R: narrow the label to slow progressors (achieved in Korea, May 2026), restart commercial production at Osong, then pursue US RMAT designation and a BLA without an additional trial.
-
Diversification of CRO end-markets: medical devices, functional foods, cosmetics materials, overseas customers.
-
Cell & gene therapy CDMO: expand contract manufacturing and development from the Osong base (thebell series, Sep 2026).
Initiatives in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Osong ATMP centre commissioning | 2024–2026 | 600 lots/year; permits obtained; comparability study pending | In progress |
| NeuroNata-R label change | Apr 2025–May 2026 | Restricted to slow progressors | Approved May 2026 |
| Rights offering & deleveraging | Aug–Nov 2025 | ~KRW 26.1 bn raised; KRW 19.1 bn for debt repayment | Completed |
| US regulatory pathway | Aug 2026 → 2027 | FDA Type C requested (9 items); RMAT then BLA targeted 2027; ~KRW 5.5 bn earmarked for FDA filing costs | Meeting expected before end-Oct 2026 |
| US research collaboration | 2025–2026 | First Korean company in WFIRM-led, NSF-backed regenerative-medicine initiative | Ongoing |
| National R&D projects | 2,026 | ≥KRW 5.4 bn incl. antibody immunotoxicity (KRW 3.0 bn), stem-cell embryo-development alternative tox (KRW 0.6 bn) | Awarded |
| Overseas CRO expansion | 2,026 | Vietnamese university hospital contract | Signed |
| Adjacent-industry testing | 2025–2026 | Functional food and cosmetic materials | Ongoing |
ESG/sustainability commitments: none identified. Cost programmes with targets: none disclosed beyond gross-margin breakeven goal.
Medium-term targets / guidance
No formal financial guidance is issued. Management statements: (i) CRO quarterly revenue ≥ KRW 10 bn as breakeven anchor; (ii) BLA submission in 2027; (iii) company estimate of ≥KRW 500 bn annual US sales potential if FDA-approved (Money Today, Apr 2026) — aspirational, not guidance.
Products & Services
Non-clinical CRO Division (former ChemOn)
| Service line | Description / capabilities | Target customer | Notes |
|---|---|---|---|
| General toxicity | Single- and repeat-dose toxicity studies in rodents and non-rodents under GLP | Drug, biologic, chemical developers | Core regulatory package for IND |
| Genetic toxicity | In vitro and in vivo genotoxicity batteries | Drug and chemical developers | — |
| Reproductive & developmental toxicity | Fertility, embryo-foetal and pre/post-natal studies | Drug developers | 2026 national project on stem-cell-based embryo-development alternative tox (KRW 0.6 bn) |
| Carcinogenicity | Long-term bioassays | Drug developers | Multi-year contracts; revenue recognition extends into 2027+ (thebell, Sep 2026) |
| Safety pharmacology | CNS, cardiovascular, respiratory and general pharmacology studies | Drug developers | — |
| Efficacy (pharmacology) testing | Study design, execution and model development for efficacy evaluation | Biotech, academia | — |
| Disease-model animals | Production and sale of disease-model animals | Researchers | Listed in IR deck |
| Alternative / advanced methods | In vitro and in vivo toxicity tests; advanced alternative test methods | Cosmetics, chemicals, pharma | Aligns with global animal-replacement trends |
| Immunotoxicity for biologics | Predictive immunotoxicity evaluation of antibody drugs | Biologic developers | 2026 national project worth KRW 3.0 bn |
| Pathology | Histopathology and clinical pathology | All study sponsors | — |
| Bioanalysis & material analysis | Test-article analysis, biological sample analysis | All study sponsors | — |
| Medical-device testing | Biocompatibility and safety testing | Device makers | Fastest-growing demand segment in 2026 (Money Today, Jun 2026) |
| Functional food & cosmetics materials testing | Safety/efficacy testing for adjacent industries | Food, cosmetics firms | Portfolio diversification initiative (IB Tomato, Apr 2026) |
| SEND data services | Instem-based SEND-compliant dataset creation for regulatory submission | Sponsors filing with FDA | ChemOn deployed Instem's preclinical suite and submit™ software via SaaS (CB Insights) |
Throughput: 1,000–1,500 studies per year (IR deck, Sep 2024). Pricing: per-study, not publicly disclosed.
Bio-pharmaceutical Division (former Corestem)
| Product / candidate | Cell type | Indication | Stage (latest) | Partners / sites | Source |
|---|---|---|---|---|---|
| NeuroNata-R (lenzumestrocel) | Autologous BM-MSC, intrathecal | ALS (slow-progressor subgroup after May 2026 label change) | Marketed in Korea (conditional 2014; label amended May 2026); US BLA targeted 2027 | Hanyang University + 4 institutions | IR deck; Money Today |
| Artificial CSF | NeuroNata-R excipient | Formulation component | Under formal review per 2024 IR timeline | — | IR deck |
| CE111BR16 | MSC | Multiple system atrophy (MSA) | Phase 1 completed | Hanyang University | IR deck |
| CE211BR19 | MSC | Cerebellar ataxia | Phase 1 completed | Yonsei Severance | IR deck |
| CE211NS21 (also cited as CE211N21) | Allogeneic BM-MSC | Neuromyelitis optica (NMO) | Phase 1 protocol submitted (2024) | SNU, Yonsei, Hanyang, Kyung Hee | IR deck |
| Astrocyte programme | iPSC / ESC | Parkinson's disease | Preclinical | — | IR deck |
| CE211AT15 | MSC | Systemic lupus erythematosus | Phase 1 completed; investigator-initiated trial completed | Hanyang University, Asan Medical Center | IR deck |
| EV231LU20 | Extracellular vesicles | Fibrosis | Preclinical | CorestemChemon | IR deck |
NeuroNata-R detail:
Mechanism: Patient's own bone-marrow-derived mesenchymal stem cells, with anti-inflammatory and immunomodulatory properties; company highlights MCP-1 (CNS-inflammation chemokine) and NfL (neurofilament light, neuronal-damage biomarker) changes.
Phase 3 (ALSUMMIT) design: 126 early-to-moderate ALS patients; double-blind, randomised, multicentre, placebo-controlled; Group 1 (26 treated), Group 2 (50 treated), Group 3 (50 control); bone-marrow extraction and repeated intrathecal injections over 12+ months with 36-month observational follow-up (IR deck, Sep 2024).
Results: Primary endpoints (Joint Rank Score incorporating ALSFRS-R and survival) not met: Group 2 vs control at 12 months p=0.118; Group 1 vs control at 6 months p=0.339 (Finance Scope, 18 Dec 2024). Company-reported post-hoc: slow-progressor subgroup met CAFS (primary) and ALSFRS-R (secondary) endpoints, with consistent SVC improvement and NfL reduction (Money Today, Jun 2026).
Commercial history: Supplied to 400+ patients in Korea; foreign patients represented ~60% of prescriptions in 2019, largely referred from US academic centres (SK Securities, Aug 2020).
Pricing: Not publicly disclosed for Korea. Company US model assumed ~KRW 100 m per administration and ~KRW 500 m per patient per year, implying ≥KRW 500 bn US annual sales at ~1,000 patients (IR deck, Sep 2024) — management projection, not guidance.
Financial Narrative
All figures consolidated, K-IFRS, KRW bn. FY2021–FY2022 include ChemOn as a 53% subsidiary; FY2023 onward reflect the merged entity. Source: Butler (DART-derived) unless noted.
Income statement
Margins and growth rates derived from reported figures. Revenue CAGR FY2021–FY2025: -9.6% (derived).
Commentary. FY2022's revenue spike to KRW 46.3 bn coincided with strong COVID-era vaccine/therapeutic non-clinical demand (ChemOn had performed non-clinical work on Korean COVID-19 vaccines and treatments, per the Dream CIS MOU announcement) and Korea's biotech funding peak; FY2022's small positive net income despite an operating loss reflects non-operating items not detailed in sources reviewed. From FY2023 the Korean biotech funding drought cut CRO orders, while Phase 3 costs and post-merger overhead widened losses. FY2025 marked the trough: CRO revenue fell 28% to KRW 19.8 bn, NeuroNata-R production stopped, and operating losses exceeded revenue. The FY2024 net loss also absorbed financing costs on convertible and exchangeable bonds; the FY2025 net loss included the full KRW 3.9 bn impairment of CRO merger goodwill (IB Tomato).
Interim trend: notes and sources
Sources: Daily Pharm (Aug 2025: H1 2025 op loss KRW 10.7 bn, revenue down 25% from KRW 15.5 bn); thebell (Oct 2025: op loss widened 25% YoY → H1 2024 ≈ KRW 8.6 bn derived; OCF -KRW 7.8 bn); thebell (Sep 2026: H1 2026 KRW 9.7 bn revenue, KRW 10.2 bn op loss; Bizwatch reports KRW 10.3 bn).
Source: thebell, Sep 2026. Q2 revenue +24.2% QoQ; gross loss narrowed 91.4%.
Balance sheet
Sources: Digital Today (FY2024 balance sheet from DART); IB Tomato (FY2025 cash, borrowings, goodwill). FY2025 equity derived from market cap ÷ PBR (KRW 100.5 bn ÷ 2.26) and is approximate.
Total debt: Short-term debt due within one year KRW 24.1 bn at end-FY2025; long-term (non-current) borrowings not disclosed in sources reviewed. Facility loans are partly secured on assets.
Net debt: at least KRW 22.0 bn (current borrowings minus cash; excludes non-current debt and bonds) — derived, understated.
Working capital: negative at end-FY2025 given current borrowings > 10× cash (derived qualitative).
Goodwill: Original KRW 3.9 bn fully impaired by FY2025.
Commentary. The November 2025 rights issue (~KRW 26.1 bn) was predominantly allocated to debt repayment (KRW 19.1 bn, of which KRW 17.3 bn executed) with KRW 6.3 bn for operations (KRW 2.1 bn used, KRW 4.2 bn remaining) (IB Tomato, Apr 2026). Despite this, cash at year-end was KRW 2.1 bn — signalling that liquidity depends on CRO recovery in 2026. The company's securities registration statement named, in descending priority, CRO retained earnings, pre-approval NeuroNata-R out-licensing, and — as a worst case — sale of the Osong ATMP centre or the CRO division as repayment sources; management later said asset sales were not under consideration.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / services |
|---|---|---|
Non-clinical CRO (R&D services) | Former ChemOn | General/genetic/reproductive toxicity, carcinogenicity, safety pharmacology, efficacy studies, pathology, bioanalysis, alternative-method testing, disease-model animals |
Cell therapy (bio-pharmaceuticals) | Former Corestem | NeuroNata-R (marketed); clinical/preclinical MSC, iPSC/ESC and EV pipeline |
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Non-clinical CRO revenue (KRW Bn) | 31.8 | 27.5 | 19.8 |
Cell therapy and other revenue (KRW Bn; FY2023 derived as residual) | 1.9 | 1.3 | 0.4 |
Total revenue (KRW Bn) | 33.7 | 28.8 | 20.2 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (%) and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
CRO share of total revenue (%) | 94.4 | 95.5 | 98.0 |
CRO revenue YoY growth (%) | — | -13.5 | -28.0 |
Cell therapy revenue YoY growth (%, reported basis) | — | — | -80 |
Revenue by Segment (Half-Yearly)
| Metric | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Total revenue (KRW Bn) | 15.5 | 11.6 | 9.7 |
CRO revenue (KRW Bn) | 14.9 | 11.3 | 9.5 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 30.2 | 46.3 | 33.7 | 28.8 | 20.2 |
Operating income (KRW Bn) | -10.5 | -6.0 | -19.7 | -22.0 | -21.2 |
Net income (KRW Bn) | -5.0 | 1.0 | -17.7 | -26.3 | -26.8 |
Revenue YoY growth (%) | — | 53.3 | -27.2 | -14.5 | -29.9 |
Operating margin (%) | -34.8 | -13.0 | -58.5 | -76.4 | -105.0 |
Net margin (%) | -16.6 | 2.2 | -52.5 | -91.3 | -132.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Revenue (KRW Bn) | 15.5 | 11.6 | 9.7 |
Operating loss (KRW Bn) | -8.6 | -10.7 | -10.2 |
Operating cash flow (KRW Bn) | — | -7.8 | — |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1 2026 | Q2 2026 |
|---|---|---|
Revenue (KRW Bn) | 4.3 | 5.4 |
Cost-of-sales ratio (%) | 136.0 | 102.5 |
Gross profit (KRW Bn) | -1.564 | -0.130 |
Balance Sheet
| Metric | FY2024 | FY2025 |
|---|---|---|
Total assets (KRW Bn) | 117.5 | — |
Total liabilities (KRW Bn) | 68.9 | — |
Total equity (KRW Bn) | 48.6 | 44.5 |
Cash and cash equivalents (KRW Bn) | — | 2.1 |
Short-term borrowings (KRW Bn) | — | 11.2 |
Current portion of long-term borrowings (KRW Bn) | — | 12.9 |
Goodwill from ChemOn merger, carrying value (KRW Bn) | — | 0.0 |
Financial Analysis
| Metric | Detail |
|---|---|
Operating cash flow | Negative in recent years; H1 2025: -KRW 7.8 bn (thebell) |
Capex | Osong cGMP/ATMP centre built Apr 2023–Aug 2024; total cost not disclosed in sources reviewed; residual equipment payments funded from 2025 offering |
Free cash flow | Negative (derived from negative OCF and capex) |
Buybacks | No buyback programme identified; treasury shares (4.78%) have been used as underlying for exchangeable bonds |
Financial Analysis — ROE
| Ratio | Value | Basis |
|---|---|---|
ROE | -62.6% (trailing) | Butler |
ROA (FY2024) | ≈ -22.4% | Derived: net loss 26.3 ÷ assets 117.5 |
Current ratio | Not publicly disclosed; implied well below 1.0× at FY2025 | Derived qualitative |
Liabilities / equity (FY2024) | 141.8% | Derived: 68.9 ÷ 48.6 |
Net debt / EBITDA | Not meaningful (negative EBITDA) | — |
Interest coverage | Negative (operating loss) | — |
Asset turnover (FY2024) | 0.25× | Derived: 28.8 ÷ 117.5 |
P/B | 2.26× | Butler |
Geography Overview
| Geography | Evidence | Trend |
|---|---|---|
Korea | CRO customers are predominantly Korean pharma/biotech/device firms and national R&D programmes; NeuroNata-R sold only in Korea | Declined FY2023–FY2025; orders recovering in 2026 |
Southeast Asia | Contract with a Vietnamese university hospital (2026) | New / nascent |
United States | No revenue; North American subsidiary (2023) and North Carolina base for regulatory/commercial preparation; participation in a WFIRM-led, NSF-backed regenerative-medicine initiative | Pre-revenue |
Foreign patients in Korea (historical) | ~60% of NeuroNata-R prescriptions in 2019 were foreign patients treated in Korea | Halted with production suspension in 2025 |
Share Price & Returns
| Reference point | Price (KRW) | Source |
|---|---|---|
~16–22 Oct 2025 | 1,648–1,680 | Digital Today |
Rights offering prelim. issue price (Aug 2025) | 1,890 | Digital Today |
Intraday reading, early Jun 2026 (post-MFDS approval) | ~2,915 | Money Today page quote |
Latest aggregator quotes, Oct 2026 | 1,901–2,020 | Butler |
Valuation Multiples
| Multiple | CorestemChemon | Note |
|---|---|---|
P/E | Not meaningful (losses) | Butler |
P/B | 2.26× | Butler |
EV/Sales (FY2025) | ≈6.1× | Derived: (market cap 100.5 + ≥22.0 net current debt) ÷ revenue 20.2; understated EV |
EV/EBITDA | Not meaningful (negative EBITDA) | — |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None identified (company "Not Rated" historically by SK Securities; Korea IR Council sponsored research only) |
Dividend history / policy | No dividends paid; no policy announced |
Buyback authorisations | None identified |
Treasury shares | 4.78%; used to back exchangeable bonds (2nd–4th series exchanged Sep 2026) |
Credit ratings (Moody's / S&P / Fitch) | None — not rated |
Debt maturity profile | KRW 11.2 bn short-term borrowings + KRW 12.9 bn current portion of long-term borrowings due within 12 months of end-FY2025; longer maturities not disclosed |
Equity raises | Nov 2025 shareholder rights offering ~KRW 26.1 bn (planned KRW 37.8 bn) |
Analyst Conclusions
Management guidance
No formal numerical guidance. Management expects (i) CRO revenue recognition from H1 2026 orders to accelerate in H2 2026, with further cost-of-sales improvement; (ii) the first goal of a quarterly gross-profit turnaround; (iii) domestic NeuroNata-R commercial production after the Osong comparability study; (iv) FDA Type C meeting before end-October 2026 and a BLA in 2027.
Consensus
No sell-side consensus is available.
Bull case
-
Operating leverage is real and visible. Q2 2026 revenue rose 24% QoQ and gross loss shrank 91%; with KRW 12.7 bn backlog and orders up 69%, a return to KRW 10 bn+ quarterly CRO revenue would, per management, cover company-wide fixed costs.
-
Regulatory derisking in Korea. MFDS approval of the narrowed label (May 2026) validates the slow-progressor/biomarker thesis and enables commercial restart from an FDA-standard plant.
-
Asymmetric US option. If FDA accepts a BLA on existing Phase 3 data (run under an FDA-cleared IND), even modest US uptake would dwarf the current ~KRW 100 bn market capitalisation.
Bear case
-
Liquidity is the binding constraint. KRW 2.1 bn cash against KRW 24.1 bn near-term borrowings (end-FY2025) leaves little room for execution slippage; further dilution or asset sales are plausible.
-
FDA scepticism toward post-hoc subgroups. Both pre-specified primary endpoints failed; FDA may require a confirmatory trial the company cannot fund.
-
Structural underperformance in CRO. Peers grew 26–43% in H1 2026 while CorestemChemon's revenue fell 16%; goodwill impairment signals the acquired CRO earns less than expected.
Catalysts and monitorables (next 12 months)
-
FDA Type C meeting (expected by end-Oct 2026) and written minutes (~30 days later)
-
Q3 2026 results (Nov 2026): CRO revenue trajectory and whether quarterly gross profit turns positive
-
Osong comparability study completion and first commercial NeuroNata-R doses
-
FY2026 business report (Mar 2027): cash position, refinancing of current borrowings, KOSDAQ listing-criteria compliance
-
RMAT application/designation; any out-licensing negotiation
-
Further capital raises, EB/CB conversions, 5%+ holder changes
-
Korean biotech financing conditions and government R&D budgets
Analyst verdict
CorestemChemon is best understood not as the ChemOn CRO the original identifier pointed to, but as a distressed hybrid in which that CRO has become the life-support system for a stem-cell programme. The CRO franchise itself retains genuine assets: a 26-year GLP heritage, an AAALAC-accredited facility, a broad toxicology menu, and fresh evidence of demand recovery — H1 2026 orders of KRW 15.2 bn and a KRW 12.7 bn backlog. Because the business is overwhelmingly fixed-cost, the revenue rebound now under way should translate quickly into margin repair, as Q2 2026's collapse in gross loss demonstrates.
The problem is time and capital. Group revenue has fallen for three straight years to KRW 20.2 bn, operating losses have exceeded KRW 19 bn in each of the last three years, and year-end FY2025 cash covered less than a tenth of borrowings due within twelve months. The November 2025 rights issue bought time by repaying debt, not by building a cushion. Meanwhile, the ChemOn goodwill has been written to zero and the company is visibly trailing listed peers that are already growing double digits.
NeuroNata-R is a legitimate but low-probability option. The May 2026 Korean label approval keeps it alive and allows a commercial restart, yet the US path rests on post-hoc subgroup and biomarker arguments after a failed pivotal trial — historically a difficult case before FDA. The late-2026 Type C feedback is therefore the single most important near-term data point: a constructive response could support partnering and non-dilutive funding; a request for a new trial would likely force further dilution or a strategic sale of assets.
On balance, the investment case is speculative and event-driven. The CRO recovery provides a credible floor narrative only if it arrives fast enough to outrun the balance sheet. Monitor quarterly gross profit, debt refinancing and FDA minutes before assigning value to the drug option.
| Item | Status |
|---|---|
| ISIN, auditor, board committee structure, outside directors | — |
| Executive compensation | — |
| Annual gross profit, EBITDA, EPS, R&D expense, capex, FCF | — |
| Geographic revenue split | — |
| Patent count | — |
| Top-10 institutional holders | — |
| ESG ratings | — |
| ChemOn standalone KOSDAQ listing date (217600) | — |
| Exact merger completion date | Conflicting (Dec 2022 per disclosures/press vs Dec 2023 per company IR deck) |
| Date of Corestem's original ChemOn stake acquisition | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / notes | Background | Source |
|---|---|---|---|---|
Yang Gil-an (양길안) | Representative Director (CEO) | — | — | IR deck 2024; thebell 2026 |
Kim Kyung-suk (김경숙) | Standing Advisor; de facto controlling shareholder | Founder of Corestem (2003); CEO through at least 2022 | Associated with Hanyang University College of Medicine (SK Securities, 2020) | Digital Today; SK Securities |
Lee Tae-yong (이태용) | Director (non-registered/unregistered officer) | Since 1 Jan 2020 | — | Digital Today (DART) |
Kim Moon-soon (김문순) | Director | — | — | Digital Today (DART) |
Song Si-hwan (송시환) | Former CEO of ChemOn (pre-merger) | — | — | Daily Pharm |
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
Kim Kyung-suk (common shares) | 8.17% (2,687,133 shares) | 21 Oct 2025 | Digital Today (DART) |
Kim Kyung-suk (including subscription rights) | 10.21% | 21 Oct 2025 | Digital Today (DART) |
Kim Kyung-suk & related parties | 26.92% (historical) | 2020 | SK Securities |
Seoul Global (venture fund, historical) | 6.58% | 2020 | SK Securities |
Treasury shares | 4.78% | Oct 2026 | Butler |
Lee Tae-yong (specified securities) | 116,392 | 21 Oct 2025 | Digital Today |
Kim Moon-soon | 2,352 (0.01%) | 22 Oct 2025 | Digital Today |
Competitive Landscape
Key Competitors
| Competitor | Type | H1 2026 revenue (KRW Bn) | H1 2026 operating income (KRW Bn) | Positioning vs CorestemChemon | Source |
|---|---|---|---|---|---|
Biotoxtech | Listed non-clinical CRO (closest pure-play peer) | 26.3 (+26%) | -2.0 | ~2.7× CorestemChemon's revenue; recovering faster | Bizwatch |
HLB Biostep | Listed non-clinical CRO | 29.5 (-6%) | -4.5 | Larger; losses narrowing | Bizwatch |
Kolmar Biotech (formerly Woojung Bio) | Listed non-clinical CRO / bio | 22.0 (+43%) | 0.4 | Returned to profit | Bizwatch |
DT&CRO | Listed non-clinical CRO | 21.4 (+6%) | -10.1 | Similar loss scale | Bizwatch |
Dream CIS | Listed clinical CRO (partner) | 37.4 (+22%) | 2.8 | Clinical, profitable | Bizwatch |
Korea Institute of Toxicology (KIT) | Government-funded GLP institute | Not applicable | Not applicable | Largest domestic GLP capacity; price/capacity benchmark | — |
C&R Research | Clinical CRO | — | Profitable (H1 2025: KRW 1.0 bn) | Clinical segment | Daily Pharm |
Bio-Infra | Clinical/bioanalytical | — | H1 2025: -3.3 | — | Daily Pharm |
Charles River Laboratories, Inotiv, WuXi AppTec, Pharmaron, JOINN | Global non-clinical CROs | — | — | Compete for Korean sponsors' FDA-bound GLP packages | — |
Competitors by Segment
| Product | Company | Type | Status | Source |
|---|---|---|---|---|
Riluzole | Sanofi (originator) | Small molecule, oral | Approved 1987 (per IR deck); generic | IR deck |
Radicava / Radicut (edaravone) | Mitsubishi Tanabe Pharma | IV / oral | Approved US 2017; oral 2022 | IR deck |
Relyvrio | Amylyx | Oral | Conditional US approval 2022; withdrawn from market (2024) | IR deck |
Qalsody (tofersen) | Biogen | Antisense, intrathecal | Accelerated approval 25 Apr 2023 for SOD1-ALS (~2% of patients) | IR deck |
NurOwn | BrainStorm Cell Therapeutics | MSC-NTF cell therapy | Phase 3 missed primary endpoint | SK Securities 2020 |
Peer Comparison FY2025
| Metric | CorestemChemon | Biotoxtech | HLB Biostep | Kolmar Biotech |
|---|---|---|---|---|
Revenue H1 2026 (KRW Bn) | 9.7 | 26.3 | 29.5 | 22.0 |
Revenue growth YoY (%) | -16.4 | 26 | -6 | 43 |
Operating margin (%) | -105.2 | -7.6 | -15.3 | 1.8 |



